RNA Pol II Inhibition Drives Apoptosis via Pol IIA Loss, Not
2026-05-13
Harper et al. (2025) demonstrate that inhibition of RNA polymerase II (RNA Pol II) activates a regulated cell death pathway through loss of hypophosphorylated RNA Pol IIA, independent of global transcriptional shutdown. This mechanistic insight reshapes our understanding of apoptosis induction in cancer cells and highlights new avenues for therapeutic targeting.
PXR Regulates Urine Concentration via Hypothalamic AVP Induc
2026-05-12
This study reveals a novel physiological role for the pregnane X receptor (PXR) in water homeostasis by demonstrating that PXR activation upregulates hypothalamic arginine vasopressin (AVP), thereby enhancing urine concentration in mice. These findings suggest new avenues for investigating PXR as a potential therapeutic target in water metabolism disorders.
ERAD-Hijacking Chimeras Enable Degradation of Transmembrane
2026-05-12
Song et al. introduce ERAD-engaging chimeras (ERADECs), a novel technology that leverages the ER-associated degradation pathway for selective elimination of challenging transmembrane proteins. This approach overcomes key limitations of previous targeted protein degradation methods, demonstrating potent efficacy in degrading PD-L1 and tumor suppression.
Anagliptin Induces Vasorelaxation via Kv Channel and SERCA A
2026-05-11
This study elucidates the vasorelaxant mechanisms of Anagliptin (SK-0403) in rabbit aortic smooth muscle, revealing that its effects are mediated through activation of voltage-dependent K+ (Kv) channels and the SERCA pump, independent of endothelium and classical cAMP/cGMP pathways. These findings enhance our understanding of DPP-4 inhibitors' cardiovascular actions and provide a mechanistic basis for future vascular pharmacology research.
Prednisolone in Glucocorticoid Signaling: Applied Research W
2026-05-11
Prednisolone, a high-purity synthetic glucocorticoid, streamlines inflammation and immunology research through its robust receptor activation and reproducible performance. This article details protocol enhancements, troubleshooting insights, and advanced experimental applications—bridging recent targeted protein degradation technologies with practical laboratory workflows for glucocorticoid signaling.
RNA Pol II Inhibition Triggers Apoptosis via PDAR, Not mRNA
2026-05-10
Harper et al. (2025) reveal that cell death from RNA Pol II inhibition arises from an active apoptotic signaling mechanism—termed the Pol II degradation-dependent apoptotic response (PDAR)—rather than the passive effects of mRNA decay. This paradigm shift has significant implications for apoptosis assay design and the mechanistic understanding of proteasome-regulated cellular processes in cancer research.
Elobixibat Hydrate’s Effects on Glucose and Lipid Metabolism
2026-05-09
This article examines a pilot study evaluating Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, in patients with type 2 diabetes mellitus (T2DM) and chronic constipation. The study demonstrates significant improvements in HbA1c, LDL cholesterol, and arachidonic acid, offering new insights into metabolic modulation beyond gastrointestinal effects.
Chlorpromazine Hydrochloride: Advanced Protocols for Antipsy
2026-05-09
Chlorpromazine hydrochloride, a benchmark dopamine D2 receptor antagonist, empowers robust antipsychotic and antiemetic research with high-purity, reproducible results. Discover optimized workflows, troubleshooting strategies, and actionable insights from the latest in hepatic nanoparticle interaction studies to accelerate your lab’s neuropharmacology and translational projects.
N6-Methyl-dATP: Bridging Epigenetic Mechanisms and Assay Inn
2026-05-08
Explore the distinct role of N6-Methyl-dATP in decoding epigenetic regulation, genomic stability, and advanced assay design. This article unpacks the molecular specificity and translational value of this methylated nucleotide, uniquely linking mechanistic insights with real-world laboratory decisions.
LDH Cytotoxicity Assay Kit: Precision Tools for Biocompatibi
2026-05-07
Discover how the LDH Cytotoxicity Assay Kit enables advanced cell cytotoxicity measurement for nanomaterial biocompatibility analysis. This article explores mechanisms, best practices, and pivotal insights that elevate your apoptosis detection and cell damage quantification strategies.
Vasopressin Analogues: Therapeutic Versatility from Hormone
2026-05-07
This review synthesizes recent advances in vasopressin analogues, focusing on their structural diversity, receptor selectivity, and expanding therapeutic roles. The paper details both classic and emerging applications, including diabetes insipidus management and potential antiviral strategies, highlighting lypressin acetate as a prime example of natural peptide drug utility.
O-Propargyl-Puromycin (OPP): Unraveling B Cell Protein Synth
2026-05-06
Explore how O-propargyl-puromycin (OPP) enables advanced, quantitative analysis of protein synthesis in B cells and reveals previously hidden links between mitochondrial function and adaptive immunity. This article uniquely connects cutting-edge mechanistic discoveries to practical assay strategy.
De Novo DPP9 Mutation Drives Hyperinflammation via Inflammas
2026-05-06
Wolf et al. reveal that a previously undescribed de novo mutation in DPP9 leads to severe infancy-onset hyperinflammation mimicking hemophagocytic lymphohistiocytosis, caused by constitutive activation of the NLRP1 and CARD8 inflammasomes. This study establishes a direct genetic link between DPP9 dysfunction and autoinflammatory disease, offering insights relevant to inflammasome regulation and dipeptidyl peptidase research.
Phebestin: Nanomolar Aminopeptidase Inhibitor Against Plasmo
2026-05-05
The reference study introduces phebestin, a bestatin-related aminopeptidase inhibitor, as a potent antiplasmodial agent with nanomolar efficacy against both chloroquine-sensitive and -resistant Plasmodium falciparum strains. This work demonstrates phebestin’s ability to disrupt blood-stage parasite development via aminopeptidase inhibition, highlighting a promising direction for overcoming malaria drug resistance.
Applied Insights: PF-04971729 (Ertugliflozin) in Diabetes &
2026-05-05
PF-04971729 (Ertugliflozin) empowers diabetes and renal glucose transport workflows through its exceptional SGLT2 selectivity and robust pharmacological profile. Discover how its nuanced mechanisms, protocol-ready solubility, and translational advantages elevate assay design and troubleshooting for both glycemic and cardiovascular studies.
461 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page